NYSE:RMD
ResMed Inc. (RMD)
Financials 
Technical Analysis 
Jul 10, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
ResMed Inc., symbol RMD-N, has garnered attention from analysts for its robust operational performance and growth potential in the respiratory care market, particularly with its CPAP machines, where it holds a dominant position. The company has surpassed earnings expectations for four consecutive quarters, indicating strong financial health and operational efficiency, with a notable return on equity of 25.81%. Despite its current PE ratio of 31.2x being significantly lower than its peak of 74.5x in 2021, future projections suggest a decrease to 27.69x, which suggests some moderation in growth. ResMed's dividend yield stands at a mere 0.76%, positioning it primarily as a growth stock rather than an income stock. Experts advise maintaining discipline in trading, with strategic stop adjustments reflecting a cautiously optimistic outlook for the stock's performance moving forward.
(A Top Pick Feb 11/16. Up 24%. Up 24%.) Sleep apnea is such an unaware market. 26% of the population have it, and the penetration is less than 15%. Last year, there was a lot of built-up demand for the masks that they create, because the new line was being rolled out. They’ve rolled out the new masks, and there has been more demand than had been expected. The dividend is just under 2%. He is continuing to buy this.
Kash Pashootan(A Top Pick Jan 11/16. Up 33.32%.) This company deals with sleep apnea by providing masks and devices. The opportunity on this is that they are very close to a refresh cycle with their masks, and there is some pent-up demand waiting for the new models to come out.
Kash PashootanThis deals with sleep apnea by producing the mask and the device that helps deliver the oxygen. 26% of adults suffer from sleep apnea. In developed markets it has only about 10%-15% penetration, and in emerging markets only 5%, so he likes the upside. Dividend yield of 2.09%.
Kash PashootanSome of the shareholders are super bright buys. They have a good shareholder base. They had a bit of a failure to launch. They don’t have a long shelf life. You have a more activist board that are shaking the tree. It is going to have prospects. He wants to see something happen with their capital.
Sleep Apnea. It is quite prevalent – 25% of the population have it. 2.12% dividend. It is the leader to provide the devices.
Kash PashootanThey address sleep apnea. It affects many more people than we think. Many have it and are not aware of it. They are the leader in the space. They build the machine and the custom mask. It is a space that is very much underpenetrated. He sees growth in the share price.
Kash Pashootan'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
(A Top Pick May 13/16. Up 30.65%.) The leader in sleep apnea, and primarily manufactures the masks. Recently sold his holdings.